Widely used:Recently Viewed
Clear All$0.89
$0.01
(1.12%)
As on 25-Apr-2025 16:22EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$144 Mln
P/E Ratio
88.85
P/B Ratio
2.59
Industry P/E
--
Debt to Equity
2.13
ROE
-5.75 %
ROCE
0.26 %
Div. Yield
0 %
Book Value
0.63
EPS
0.01
CFO
$440.27 Mln
EBITDA
$505.10 Mln
Net Profit
$-1,021.16 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc. Class A (IRWD)
| -79.94 | -40.37 | -76.05 | -89.03 | -58.22 | -38.72 | -23.32 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc. Class A (IRWD)
| -60.98 | -7.67 | 6.26 | 2.37 | -14.43 | 53.49 | -30.75 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase... type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Read more
Executive Chairman of the Board
Ms. Julie H. McHugh
Executive Chairman of the Board
Ms. Julie H. McHugh
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Ironwood Pharmaceuticals Inc Class A (IRWD) stood at $ 351 Mln as on 31-Dec-24
The share price of Ironwood Pharmaceuticals Inc Class A (IRWD) is $0.89 (NASDAQ) as of 25-Apr-2025 16:22 EDT. Ironwood Pharmaceuticals Inc Class A (IRWD) has given a return of -58.22% in the last 3 years.
Ironwood Pharmaceuticals Inc Class A (IRWD) has a market capitalisation of $ 144 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Ironwood Pharmaceuticals Inc Class A (IRWD) is 88.85 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ironwood Pharmaceuticals Inc Class A (IRWD) and enter the required number of quantities and click on buy to purchase the shares of Ironwood Pharmaceuticals Inc Class A (IRWD).
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
The CEO & director of Ms. Julie H. McHugh. is Ironwood Pharmaceuticals Inc Class A (IRWD), and CFO & Sr. VP is Ms. Julie H. McHugh.
There is no promoter pledging in Ironwood Pharmaceuticals Inc Class A (IRWD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Ironwood Pharmaceuticals Inc. Class A (IRWD) | Ratios |
|---|---|
|
Return on equity(%)
|
-0.72
|
|
Operating margin(%)
|
27.95
|
|
Net Margin(%)
|
0.25
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ironwood Pharmaceuticals Inc Class A (IRWD) was $0 Mln.
